Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Genelux Corp., retaining the price target of $10.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors that highlight the potential of Genelux Corp. in the oncolytic virus (OV) space. One of the key reasons is the company’s lead OV asset, Olvi-Vec, which is in late-stage development for platinum-resistant ovarian cancer. Olvi-Vec offers a unique advantage with its systemic and intraperitoneal delivery methods, which could potentially resensitize tumors to platinum-based treatments, thereby enhancing its effectiveness.
Furthermore, the upcoming clinical milestones for Genelux, including the Phase 3 trial results for ovarian cancer expected in the first half of 2026, and interim data for non-small cell lung carcinoma in the second half of 2025, are significant catalysts. These developments, coupled with the potential approval of Replimune’s OV asset, which could bring more attention to the OV space, position Genelux as an attractive investment opportunity. McCarthy also notes that Genelux is trading at a discount compared to its peers, making it an appealing choice for investors looking to capitalize on the evolving OV market.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GNLX in relation to earlier this year.